학술논문
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
Document Type
Article
Author
Source
In Annals of Oncology November 2020 31(11):1536-1544
Subject
Language
ISSN
0923-7534